Idera's TLR9 agonist plus Yervoy leads to 38% ORR in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported data from 21 evaluable metastatic melanoma patients who progressed on anti-PD-1 therapy in the Phase II portion of the Phase I/II ILLUMINATE-204 (2125-204) trial showing that 8 mg/kg intratumoral tilsotolimod (IMO-2125) plus anti-CTLA-4 mAb Yervoy ipilimumab led to a confirmed overall response rate (ORR) of 38.1%, including two complete responses and six partial responses. Median duration of response has not yet been reached. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The trial is enrolling up to 60 patients to receive the 8 mg/kg dose of tilsotolimod, with enrollment slated to be completed by year end. Idera previously reported data from the Phase I portion of the open-label, U.S. trial (see BioCentury, Oct. 17, 2016)...